K-numberK260509
Device nameAutoContour (RADAC V5)
ApplicantRadformation, Inc.
Product codeQKB
Device classClass II
Decision dateMar 19, 2026
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

AutoContour Model RADAC V5 is a software-only medical device that automatically contours anatomical structures in CT and MR images to assist radiation treatment planners in preparing for radiation therapy. It uses deep-learning-based structure models trained on multi-institutional imaging datasets to generate initial contours that users can review, modify, and export as DICOM-compliant structure sets for import into radiation therapy treatment planning systems.

Technological characteristics

The device consists of three components: a .NET client application for Windows, a local Windows agent service, and a cloud-based automatic contouring service. It supports CT or MR input for contouring and registration/fusion, with PET/CT input for registration/fusion only. RADAC V5 includes 420 CT-based and 62 MR-based structure models, expanding from the predicate's 260 CT and 35 MR models. Core functionality, data visualization/GUI, and view manipulation capabilities (window/level, pan, zoom, registration) remain equivalent to the predicate.

Test standards cited

Not stated in this summary. The document references internal validation protocols and qualitative Likert-scale reviews by clinical experts, but does not cite specific external consensus standards (ISO, IEC, ASTM, etc).

Substantial equivalence argument

RADAC V5 is substantially equivalent to AutoContour Model RADAC V4 (K242729) because indications for use, patient population, intended users, energy delivery, and core functionality remain unchanged. Verification testing confirmed that features and performance meet predefined acceptance criteria consistent with the predicate. New and updated structure models passed rigorous testing (DSC and Hausdorff Distance metrics) with external clinical validation, and unchanged models passed regression testing. Minor technological differences—primarily the addition of new structure models and integration of models from the reference device Limbus Contour—do not raise significant safety or effectiveness concerns.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →